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Cochrane Collaborative Review Group on Peripheral Vascular Diseases:
Review Abstracts
Introduction Abstracts
The following abstracts are part of an ongoing series Abstract. Buflomedil for intermittent claudication.
T. L. M. De Backer, R. H. Vander Stichele, and M.G.of articles produced by the Cochrane Collaborative
Review Group on Peripheral Vascular Diseases, which Bogaert
Date of most recent substantive amendment:is part of the Cochrane Collaboration. The reviews are
published in full on The Cochrane Library, a quarterly 21 February 2000
electronic journal available on CD-ROM and via the
Internet. The electronic format allows Cochrane re-
views to accommodate new data as they become avail-
Backgroundable, making the library a consistently up-to-date
source of information over time.
Intermittent claudication is pain, caused by chronic
occlusive arterial disease, that develops in a limb
The abstracts appearing on the Cochrane Library during exercise and is relieved with rest.
are now presented in a different, simpler, less scientific
format than the abstracts usually presented here to Buflomedil is a vasoactive agent claimed to have
permit greater accessibility to the public. However, beneficial effects on the microcirculation. It is used
the substance of both versions is the same. Review chiefly to treat peripheral vascular disease and to
abstracts on Cochrane reviews will be indexed on a lesser extent for cerebrovascular arterial disease.
MedLine in the near future. However, its clinical efficacy for intermittent clau-
dication has not previously been examined critically.
If you are interested in writing a Cochrane review
or contributing to the activities of the Cochrane Peri-
pheral Vascular Diseases Group please contact:
Objectives
Professor FGR Fowkes
To evaluate the available evidence on the efficacy ofCochrane Collaborative Review Group on Peripheral
buflomedil for intermittent claudication.Vascular Diseases
Public Health Sciences
University of Edinburgh
Teviot Place Search strategy
Edinburgh EH8 9AG
Tel. +44 (0) 131 650 3220 Trial reports were sought through Medline, Inter-
Fax. +44 (0) 131 650 6904 national Pharmaceutical Abstracts (IPA) and the Coch-
rane Controlled Trials Register. Abbott Laboratories,
the distributor of buflomedil, was asked to provideAny comments or criticisms on these Cochrane re-
views/abstracts should be made through the com- reports of controlled clinical trials. Reference lists of
retrieved articles were checked, and enquiries sent toments/criticisms facility on the Cochrane Library, or
by contacting the group at the above address. authors of known trials, to identify additional trials.
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Finally, the authors conducted a Science Citation Index Reviewers’ conclusions
search.
There is little evidence available to evaluate the efficacy
of buflomedil for intermittent claudication. Most avail-
able trials are of poor quality and were excluded from
the review. The two trials included showed moderately
Selection criteria positive results but these are undermined by pub-
lication bias since we know of another four un-Trial reports had to be double-blinded, randomised, published, irretrievable, and inconclusive studies.and conformed to our PIO-criteria (Patients, Inter-
vention, Outcome) to be considered for inclusion. There is a lack of evidence for the efficacy of bu-
Patients were required to have proven intermittent flomedil in intermittent claudication.
claudication (Fontaine stage II); the intervention was
to be oral administration of buflomedil compared to
placebo; and outcomes had to include pain-free walk- Abstract. Home versus in-patient treatment for deep
ing distance (PFWD) and maximum walking distance vein thrombosis
(MWD) analysed by standardised exercise test. I. G. Schraibman, A. A. Milne, and E. M. Royle
Date of most recent substantive amendment:
6 February 2001
Data collection and analysis
Background
Searches of bibliographic databases yielded three eli-
Deep vein thrombosis (DVT) affects 1–2/1,000 of thegible randomised controlled trials (RCTs) and a meta-
adult population per annum in western societies. Itanalysis referring to nine eligible trials. Two of these
may be associated with pulmonary embolism (PE)nine trials had already been identified; two had been
which carries a 10% fatality rate. Sufferers may developpublished in journals not referenced in traditional
post-thrombotic syndrome with swelling of the leg,bibliographic indexes; and five were unpublished. De-
secondary varicose veins and ulceration. In the initialspite multiple requests, details of only one of the five
stages of treatment for DVT, patients are traditionallyunpublished trials were provided by the author of the
admitted to hospital for intravenous treatment withmeta-analysis, the other four could not be retrieved.
unfractionated heparin (UH) for three to five days.Four of the six eligible trials retrieved were sub-
The dose of UH required to provide a therapeuticsequently excluded after quality evaluation.
level of anticoagulation is unpredictable, so the blood
must be closely monitored. Fractionated, or low mo-
Data on walking distances were extracted from the lecular weight heparin (LMWH), is given sub-
two remaining trials. Differences in incremental gain cutaneously once daily and requires no monitoring,
between active and placebo groups for PFWD and so can be given in hospital or at home.
MWD with their confidence intervals were calculated.
Objectives
To collate all randomised controlled trials (RCTs) com-Main results
paring a home treatment regime (LMWH) with hos-
pital treatment (LMWH or UH) for the initial phaseBoth RCTs included in the review showed moderate
of treatment for DVT, and to compare the safety,improvements in PFWD for patients on buflomedil.
efficacy, patient acceptability and cost implications ofIn one trial this improvement (75 m, 95% CI 37–114)
home versus in-patient treatment.was statistically significant, but in the other, with a
wholly diabetic population, it was non-significant
(81 m, 95% CI−9–170) compared to placebo. For both
RCTs the gains in MWD were statistically significant, Search strategy
but with wide confidence intervals (81 m, 95% CI
30–131; and 171 m, 95% CI 27–316 respectively). Pool- All published reports of home treatment were traced
through MEDLINE, and EMBASE (up to and includinging of the data was not attempted.
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December 2000) using the search strategy described Main results
by the Cochrane Peripheral Vascular Diseases Group.
Additional searches included the Cochrane CCTR/ Only two major RCTs with comparable treatment arms
were found. Both had fundamental problems, in-CENTRAL database, handsearching non-listed
journals, and personal communication with re- cluding high exclusion rates, partial hospital treatment
of many in the LMWH arms, and comparison of UHsearchers.
in hospital with LMWH at home. The trials showed
that home treatment was no more liable to com-
plications than hospital treatment. Initial results from
Selection criteria a smaller RCT comparing LMWH treatment in both
home and hospital arms came to the same conclusion.
RCTs of home versus hospital treatment for DVT in
which DVT was clinically confirmed and treated with
either LMWH or UH.
Reviewers’ conclusions
Data collection and analysis
The limited evidence suggests that home management
is cost effective, and likely to be preferred by patients.One reviewer selected the material for inclusion (IGS):
another (AAM) reviewed the literature and selection Further large trials comparing these treatments are
unlikely to be held. Therefore, home treatment is likelyof trials, and the third (EMR) cross-checked the data.
Outcomes included PE, recurrent DVT, gangrene, hep- to become the norm, and further research will be
directed to resolving practical issues.arin complications, and death.
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